Metabolic bone disease: Atypical femoral fractures

Journal of Biomechanics

Volumn 44, Issue 2, 2011, Pages 244-247

  Singer, Frederick R ^a,b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Bone biopsies; Femoral fractures; Postmenopausal women

Indexed keywords

BISPHOSPHONATES; BONE BIOPSIES; BONE CELLS; BONE DISEASE; BONE STRUCTURE; FEMORAL FRACTURES; FEMORAL SHAFT; MAJOR FACTORS; METABOLIC BONE DISEASE; POSTMENOPAUSAL WOMEN;

BIOPSY; BONE; MAMMALS; METABOLISM;

FRACTURE;

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PLACEBO; TETRACYCLINE; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; ARTICLE; BONE BIOPSY; BONE CELL; BONE STRUCTURE; BONE TURNOVER; CELL ACTIVITY; CELL COUNT; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMUR SHAFT FRACTURE; HUMAN; HYPOPHOSPHATASIA; INHIBITION KINETICS; METABOLIC BONE DISEASE; MORPHOMETRICS; OSTEOBLAST; OSTEOCLAST; PAGET BONE DISEASE; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; X LINKED HYPOPHOSPHATEMIC RICKETS;

AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BIOPSY; BONE AND BONES; BONE DISEASES, METABOLIC; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FEMUR; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE; RANK LIGAND;

EID: 78650971584     PISSN: 00219290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiomech.2010.10.013     Document Type: Article

References (26)

1. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. Journal of Bone and Mineral Research 2009, 24:1095-1102.
2. Anderton J.M. Orthopaedic problems in adult hypophosphatasia: a report of two cases. Journal of Bone and Joint Surgery Br 1979, 61:82-84.
3. Armstrong D.G., Newfield J.T., Gillespie R. Orthopedic management of osteopetrosis-results of a survey and review of the literature. Journal of Pediatric Orthopaedics 1999, 19:122-132.
4. Ascenzi A. The micromechanics versus the macromechanics of cortical bone - a comprehensive presentation. Journal of Biomechanical Engineering 1988, 110:357-363.
5. Ascenzi M.-G., Lomovtsev A. Collagen orientation patterns in human secondary osteons, quantified in the radial direction by confocal microscopy. Journal of Structural Biology 2006, 153:14-30.
6. Ascenzi M.-G., Benvenuti A., Ascenzi A. Single osteon micromechanical testing. Mechanical Testing of Bone 2000, 271-290. CRC Press, Boca Raton, FL. Y. An, R. Draughn (Eds.).
7. Ascenzi, M.-G., Keyak, J.H., 2010. Towards patient-specific hierarchical simulation of proximal femur. In: Proceedings of the 56th annual meeting, Orthopaedic Research Society, New Orleans, LA.
8. Bamrungsong T., Pongchaiyakul C. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. Journal of the Medical Association of Thailand 2010, 93:620-624.
9. Bilezikian J.P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. American Journal of Medicine 2009, 122:S14-21.
10. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., Cauley J., Leung P.C., Boonen S., Santora A., de Papp A., Bauer D.C. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New England Journal of Medicine 2010, 362:1761-1771.
11. Das De, S., Setiobudi T., Shen L., Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. Journal of Bone and Joint Surgery British 2010, 92:679-686.
12. Dove J. Complete fractures of the femur in Paget's disease of bone. Journal of Bone and Joint Surgery British 1980, 62-B:12-17.
13. Edwards M.H., McCrae F.C., Young-Min S.A. Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporosis International 2010, 21:701-703.
14. Esterberg J., Kassim R.A., Redmon J., Coad J., Macari G.S., Saleh K.J. Hip pain in a case of hypophosphatemic osteomalacia. American Journal of Orthopaedics (Belle Mead NJ) 2003, 32:455-458.
15. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T., Howe T.S. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. Journal of Bone and Joint Surgery. British Volume 2007, 89:349-353.
16. Keyak J.H., Kaneko T.S., Rossi S.A., Pejcic M.R., Tehranzadeh J., Skinner H.B. Predicting the strength of femoral shafts with and without metastatic lesions. Clinical Orthopaedics and Related Research 2005, 439:161-170.
17. Lee J.K. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. International Journal of Rheumatic Diseases 2009, 12:149-154.
18. Lee P. Atypical femoral fractures. Canadian Medical Association Journal 2010, 182:384-385.
19. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. New England Journal of Medicine 2008, 358:1304-1306.
20. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., van der Meulen M.C., Lorich D.G., Lane J.M. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporosis International 2009, 20:1353-1362.
21. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. Journal of Orthopaedic Trauma 2008, 22:346-350.
22. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. Journal of Clinical Endocrinology and Metabolism 2005, 90:1294-1301.
23. Reid, I., Miller, P., Brown, J., Kendler, D., Fahrleitner-Pammer, A., Valter, I., Maasalu, K., Bolognese, M., Woodson, G., Bone, H., Ding, B., Wagman, R., Martin, J.S., Ominsky, M., Dempster, D., 2010 Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. Journal of Bone and Mineral Research 25, 2256-2265.
24. Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. Journal of Bone and Mineral Research 2009, 24:1736-1740.
25. Spivacow F.R., Sarli M., Buttazzoni M. Treatment with bisphosphonates and atypical fractures. Medicina (B Aires) 2009, 69:612-618.
26. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. Journal of Clinical Endocrinology and Metabolism 2008, 93:2948-2952.